Innovent and Lilly Present Results of Tyvyt (sintilimab) in P-III ORIENT-3 Trial as 2L Treatment for Advanced or Metastatic Squamous NSCLC at AACR 2021

April 14, 2021 Auto Bot Advanced, Clinical Trials, Innovent, Lilly, Metastatic, results, Sintilimab, Treatment, Tyvyt 0

Shots:

  • The P-III ORIENT-3 trial involves assessing the efficacy and safety of Tyvyt (sintilimab) vs docetaxel (q3w) in 290 patients in a ratio (1:1) as a 2L treatment for advanced or m-sqNSCLC
  • The trial met its 1EP i.e improvement in OS, mOS (11.79 vs 8.25 mos.), mPFS (4.30 vs 2.79 mos.), ORR (25.5% vs 2.2%), safety was consistent with previous studies, and no new safety signals were identified
  • Currently, NMPA has three Tyvyt’s sNDA under review which include sNDA for 1L therapy in squamous NSCLC, 1L therapy in HCC, and 2L therapy in sqNSCLC

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Lixoft

The post Innovent and Lilly Present Results of Tyvyt (sintilimab) in P-III ORIENT-3 Trial as 2L Treatment for Advanced or Metastatic Squamous NSCLC at AACR 2021 first appeared on PharmaShots.